Ramin Khoramnia (University Eye Clinic Heidelberg, Heidelberg, Germany) discusses imitations of current treatment options for neovascular age-related macular degeneration, gives an overview of faricimab, its dosing regimen and its mechanism of action and discusses the major efficacy and safety findings of the STAIRWAY study, which were presented at WOC 2020.
1. What are the limitations of current treatment options for neovascular age-related macular degeneration? (0:05)
2. Could you give us an overview of faricimab, its dosing regimen and its mechanism of action? (1:07)
3. What were the aims and design of the STAIRWAY study? (2:07)
4. What were the major efficacy and safety findings of this study? (2:54)
5. What is the potential for combining faricimab with angiopoietin-2 and vascular endothelial growth factor inhibitors and what future studies are planned? (3:33)
Disclosures: Ramin Khoramnia has received grant support from: Alimera, Bayer, Chengdu Kanghong, Novartis, and Roche; travel support from: Alimera, Allergan, Bayer, Novartis, and Roche; and lecture fees from: Alimera, Allergan, Bayer, Novartis, and Roche.
touchOPHTHALMOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Commissioned, edited and funded by Touch Medical Media
Published: 31 July 2020
Share this Video
Related Videos In Macular Degeneration
Carl Regillo, Hawaiian Eye and Retina 2021: Geographic Atrophy – Current Therapeutic Approaches and Future Prospects
It was a pleasure to catch up with Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA), who talked us through the therapeutic approaches currently in clinical trial investigation for the treatment of geographic atrophy, and his views on exciting future prospects for treatment. Questions Could you give us a brief overview of the therapeutic approaches […]
Carl Regillo, Hawaiian Eye and Retina 2021: Geographic Atrophy – Incidence and Prognosis
We enjoyed speaking to Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA) about incidence and prognosis of geographic atrophy, and advances in understanding of genetics and pathophysiology of dry AMD. Questions Could you give us a brief overview of geographic atrophy, its incidence and prognosis? (00:17) Why have we failed to achieve the same breakthroughs […]
Assaf Hilely, ESCRS 2020 – Non-neovascular Age-related Macular Degeneration with Subretinal Fluid
We caught up with Editorial Board member Dr Assaf Hilely (Tel Aviv Medical Center, Tel Aviv, Israel), who talked us through his recent study of non-neovascular age-related macular degeneration with subretinal fluid. Questions What prognostic factors are currently used to guide treatment when initiating anti-vascular endothelial growth factor treatment for patients with age-related macular degeneration […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!